ILTOO Pharma announces the results of a Phase IIb trial for ALS using Low-Dose IL-2

ILTOO Pharma announces the results of a Phase IIb trial for ALS using Low-Dose IL-2. ILTOO Pharma SAS today announced the results of MIROCALS, a Phase IIb trial in amyotrophic lateral sclerosis (ALS) using low-dose Interleukine-2 (IL-2LD), which were presented by Dr. Gilbert Bensimon at the International Symposium on ALS / Motor Neuron Diseases.

The release as fetched from its publisher. iltoopharma.com ↗